Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation
Background. According to the some studies tocilizumab therapy (TCZ) in patients with rheumatoid arthritis (RA) is accompanied by deterioration of blood lipid profile. Aim. To study changes in serum lipid parameters in patients with RA treated with a combination of tocilizumab and methotrexate compar...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/325 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227972243881984 |
|---|---|
| author | E. V. Udachkina D. S. Novikova T. V. Popkova E. Yu. Panasyuk A. S. Avdeeva A. V. Volkov I. G. Kirillova E. I. Markelova E. N. Aleksandrova A. A. Novikov E. L. Nasonov |
| author_facet | E. V. Udachkina D. S. Novikova T. V. Popkova E. Yu. Panasyuk A. S. Avdeeva A. V. Volkov I. G. Kirillova E. I. Markelova E. N. Aleksandrova A. A. Novikov E. L. Nasonov |
| author_sort | E. V. Udachkina |
| collection | DOAJ |
| description | Background. According to the some studies tocilizumab therapy (TCZ) in patients with rheumatoid arthritis (RA) is accompanied by deterioration of blood lipid profile. Aim. To study changes in serum lipid parameters in patients with RA treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation. Material and methods. Patients (n=72) with RA were included into the pilot non-randomized 24-week study and divided in two groups: 1) TCZ+MTX group (n=39; women 30; median age 51 [43-55] years; 6 i.v. infusions of TCZ 8 mg/kg + МТX 10-20 mg/week); 2) MTX group (n=33; women 23; mеdian age 56 [48-63] years; MTX 7.5-20 mg/week). Results. At the baseline, similar proatherogenic blood profile was observed in both groups. The patients of MTX group more frequently took statins (n=19; 57.6%) compared with the group TCZ+MTX (n=7; 18%), (p<0.05). The lipid levels correlated positively with traditional risk factors (p<0.05). RA activity and duration correlated negatively with high density lipoprotein cholesterol (HDL-C), (p<0.05). Good/satisfactory anti-inflammatory effect was achieved in both groups after 24 weeks of treatment. Patients of TCZ+MTX group showed an increase in total cholesterol and HDL-C levels by 11% and 110%, respectively and decrease in plasma atherogenic index (PAI) by 47%, (p<0.05). HDL-C level increased by 22% and PAI decreased by 16% in patients of MTX group (p<0.05). Among patients of MTX group without statin therapy HDL-C as well as non-HDL-C levels were increased by 24% and 27%, respectively (p<0.05); PAI did not change significantly in this subgroup. Among patients of MTX group treated with statins isolated increase in HDL-C level by 22% and decrease in PAI by 37.3% (p<0.05) were observed. A number of patients with achieved target levels of all studied lipid parameters did not change significantly in both groups. Conclusions. TCZ+MTX combined therapy as well as MTX monotherapy are associated with similar improvement in lipid parameters. Adjusted statin doses may be needed to achieve target serum lipid profile in RA patients. |
| format | Article |
| id | doaj-art-d5bbb68750944b14bc6e2c989452f992 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2015-11-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-d5bbb68750944b14bc6e2c989452f9922025-08-23T10:00:18ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-11-0111551051610.20996/1819-6446-2015-11-5-510-516325Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observationE. V. Udachkina0D. S. Novikova1T. V. Popkova2E. Yu. Panasyuk3A. S. Avdeeva4A. V. Volkov5I. G. Kirillova6E. I. Markelova7E. N. Aleksandrova8A. A. Novikov9E. L. Nasonov10V.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaV.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaV.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaV.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaV.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaV.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaV.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaV.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaV.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaV.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaV.A. Nasonova Research Institute of Rheumatology, Kashirskoe shosse 34A, Moscow, 155522 RussiaBackground. According to the some studies tocilizumab therapy (TCZ) in patients with rheumatoid arthritis (RA) is accompanied by deterioration of blood lipid profile. Aim. To study changes in serum lipid parameters in patients with RA treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation. Material and methods. Patients (n=72) with RA were included into the pilot non-randomized 24-week study and divided in two groups: 1) TCZ+MTX group (n=39; women 30; median age 51 [43-55] years; 6 i.v. infusions of TCZ 8 mg/kg + МТX 10-20 mg/week); 2) MTX group (n=33; women 23; mеdian age 56 [48-63] years; MTX 7.5-20 mg/week). Results. At the baseline, similar proatherogenic blood profile was observed in both groups. The patients of MTX group more frequently took statins (n=19; 57.6%) compared with the group TCZ+MTX (n=7; 18%), (p<0.05). The lipid levels correlated positively with traditional risk factors (p<0.05). RA activity and duration correlated negatively with high density lipoprotein cholesterol (HDL-C), (p<0.05). Good/satisfactory anti-inflammatory effect was achieved in both groups after 24 weeks of treatment. Patients of TCZ+MTX group showed an increase in total cholesterol and HDL-C levels by 11% and 110%, respectively and decrease in plasma atherogenic index (PAI) by 47%, (p<0.05). HDL-C level increased by 22% and PAI decreased by 16% in patients of MTX group (p<0.05). Among patients of MTX group without statin therapy HDL-C as well as non-HDL-C levels were increased by 24% and 27%, respectively (p<0.05); PAI did not change significantly in this subgroup. Among patients of MTX group treated with statins isolated increase in HDL-C level by 22% and decrease in PAI by 37.3% (p<0.05) were observed. A number of patients with achieved target levels of all studied lipid parameters did not change significantly in both groups. Conclusions. TCZ+MTX combined therapy as well as MTX monotherapy are associated with similar improvement in lipid parameters. Adjusted statin doses may be needed to achieve target serum lipid profile in RA patients.https://www.rpcardio.online/jour/article/view/325rheumatoid arthritistocilizumabmethotrexatlipidsstatins |
| spellingShingle | E. V. Udachkina D. S. Novikova T. V. Popkova E. Yu. Panasyuk A. S. Avdeeva A. V. Volkov I. G. Kirillova E. I. Markelova E. N. Aleksandrova A. A. Novikov E. L. Nasonov Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation Рациональная фармакотерапия в кардиологии rheumatoid arthritis tocilizumab methotrexat lipids statins |
| title | Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation |
| title_full | Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation |
| title_fullStr | Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation |
| title_full_unstemmed | Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation |
| title_short | Changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation |
| title_sort | changes in serum lipids in patients with rheumatoid arthritis treated with a combination of tocilizumab and methotrexate compared with methotrexate alone for 24 weeks of observation |
| topic | rheumatoid arthritis tocilizumab methotrexat lipids statins |
| url | https://www.rpcardio.online/jour/article/view/325 |
| work_keys_str_mv | AT evudachkina changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation AT dsnovikova changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation AT tvpopkova changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation AT eyupanasyuk changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation AT asavdeeva changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation AT avvolkov changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation AT igkirillova changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation AT eimarkelova changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation AT enaleksandrova changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation AT aanovikov changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation AT elnasonov changesinserumlipidsinpatientswithrheumatoidarthritistreatedwithacombinationoftocilizumabandmethotrexatecomparedwithmethotrexatealonefor24weeksofobservation |